Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More